FDA accepts Psyadon Pharmaceuticals' ecopipam IND for treatment of LND

Links shared publicly online about this topic.

1,395
total visits

FDA accepts Psyadon Pharmaceuticals' ecopipam IND for treatment of LND

Psyadon Pharmaceuticals, Inc. today announced that the United States Food and Drug Administration (FDA) has accepted its Investigational New Drug Application (IND) to study ecopipam in patients with Lesch-Nyhan Disease (LND). The first center at which the drug will be evaluated is Emory University under the direction of Dr. Hyder A. Jinnah, MD, PhD. The study is designed to evaluate the safety and tolerability of different doses of ecopipam in adults (group 1), adolescents (group 2) and children

View full resource at news-medical.net

Tags: Disease and Condition, Drug, Pharma, Children's Health, FDA, Doctor